In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Head-long Leap into Follow-On Biologics

Executive Summary

Merck outlined ambitious and capital-intensive plans for a biosimilars business at its annual investor day in early December. The company aims to leverage its 2006 acquisition of GlycoFi to launch six or more follow-on biologics between 2012 and 2017. The news shifts the Big Pharma in an entirely new direction, one that pharmaceutical companies--with the exception of Novartis AG's Sandoz division--have largely stayed away from.
Advertisement

Related Content

Opening A Door To Biosimilars In The US
Health Care Reform: For Biopharmas There Is Much To Like
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2009
Pharma R&D: Doing the Same Thing That Didn't Work Before
A Two Pharma Horse Race In Follow-On Biologics
Biopharma in 2008: What a Difference an Economic Crisis Makes
Pharma's New Follow-On Strategy
Pharma's New Follow-On Strategy
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel